Spina Bifida In Utero Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major spina bifida in utero markets are expected to exhibit a CAGR of 6.59% during 2024-2034.
The spina bifida in utero market has been comprehensively analyzed in IMARC's new report titled "Spina Bifida In Utero Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Spina bifida in utero refers to a congenital neural tube defect that occurs during early fetal development, where the neural tube, which eventually forms the spinal cord, fails to close completely. This condition leads to incomplete development of the spinal cord and the surrounding vertebrae. The symptoms of the disorder can differ widely, ranging from mild to severe. Common indications include motor and sensory deficits, difficulty walking, bladder and bowel control issues, and, in more severe cases, paralysis and hydrocephalus (accumulation of cerebrospinal fluid in the brain). The intensity of symptoms largely depends on the extent of the spinal cord and nerve involvement. The diagnosis of spina bifida in utero often involves prenatal screening methods, such as ultrasound and maternal serum alpha-fetoprotein (AFP) tests. These investigations can help to identify potential abnormalities in the developing fetus's spine and provide crucial information for early intervention and treatment planning.
The increasing prevalence of mutations or dysfunction in genes like VANGL1, which is implicated in the proper closure of the neural tube, is primarily driving the spina bifida in utero market. In addition to this, the inflating utilization of efficacious medications, such as folic acid supplementation preconception and in early pregnancy, to mitigate the impact and progression of the ailment is also creating a positive outlook for the market. Moreover, the widespread adoption of surgical interventions like in utero myelomeningocele repair that are designed to minimize neural damage and improve postnatal function is further bolstering the market growth. Apart from this, the rising usage of advanced diagnostic techniques, such as prenatal imaging through ultrasound and maternal serum screening, is acting as another significant growth-inducing factor. These approaches empower healthcare providers with critical insights into the condition's severity, enabling them to formulate comprehensive strategies for optimal care. Additionally, the emerging popularity of multidisciplinary approaches, encompassing physical therapy and assistive devices, to bolster mobility, muscle strength, and overall functionality is also augmenting the market growth. Furthermore, the escalating demand for regenerative medicine, including stem cell therapy and tissue engineering, since they work by harnessing the body's innate healing mechanisms to restore damaged neural tissues, is expected to drive the spina bifida in utero market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the spina bifida in utero market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for spina bifida in utero and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the spina bifida in utero market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the spina bifida in utero market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the spina bifida in utero market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current spina bifida in utero marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the spina bifida in utero market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the spina bifida in utero market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the spina bifida in utero market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of spina bifida in utero across the seven major markets?
What is the number of prevalent cases (2018-2034) of spina bifida in utero by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of spina bifida in utero by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with spina bifida in utero across the seven major markets?
What is the size of the spina bifida in utero patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of spina bifida in utero?
What will be the growth rate of patients across the seven major markets?
Spina Bifida In Utero: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for spina bifida in utero drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the spina bifida in utero market?
What are the key regulatory events related to the spina bifida in utero market?
What is the structure of clinical trial landscape by status related to the spina bifida in utero market?
What is the structure of clinical trial landscape by phase related to the spina bifida in utero market?
What is the structure of clinical trial landscape by route of administration related to the spina bifida in utero market?
The spina bifida in utero market has been comprehensively analyzed in IMARC's new report titled "Spina Bifida In Utero Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Spina bifida in utero refers to a congenital neural tube defect that occurs during early fetal development, where the neural tube, which eventually forms the spinal cord, fails to close completely. This condition leads to incomplete development of the spinal cord and the surrounding vertebrae. The symptoms of the disorder can differ widely, ranging from mild to severe. Common indications include motor and sensory deficits, difficulty walking, bladder and bowel control issues, and, in more severe cases, paralysis and hydrocephalus (accumulation of cerebrospinal fluid in the brain). The intensity of symptoms largely depends on the extent of the spinal cord and nerve involvement. The diagnosis of spina bifida in utero often involves prenatal screening methods, such as ultrasound and maternal serum alpha-fetoprotein (AFP) tests. These investigations can help to identify potential abnormalities in the developing fetus's spine and provide crucial information for early intervention and treatment planning.
The increasing prevalence of mutations or dysfunction in genes like VANGL1, which is implicated in the proper closure of the neural tube, is primarily driving the spina bifida in utero market. In addition to this, the inflating utilization of efficacious medications, such as folic acid supplementation preconception and in early pregnancy, to mitigate the impact and progression of the ailment is also creating a positive outlook for the market. Moreover, the widespread adoption of surgical interventions like in utero myelomeningocele repair that are designed to minimize neural damage and improve postnatal function is further bolstering the market growth. Apart from this, the rising usage of advanced diagnostic techniques, such as prenatal imaging through ultrasound and maternal serum screening, is acting as another significant growth-inducing factor. These approaches empower healthcare providers with critical insights into the condition's severity, enabling them to formulate comprehensive strategies for optimal care. Additionally, the emerging popularity of multidisciplinary approaches, encompassing physical therapy and assistive devices, to bolster mobility, muscle strength, and overall functionality is also augmenting the market growth. Furthermore, the escalating demand for regenerative medicine, including stem cell therapy and tissue engineering, since they work by harnessing the body's innate healing mechanisms to restore damaged neural tissues, is expected to drive the spina bifida in utero market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the spina bifida in utero market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for spina bifida in utero and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the spina bifida in utero market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the spina bifida in utero market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the spina bifida in utero market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current spina bifida in utero marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the spina bifida in utero market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the spina bifida in utero market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the spina bifida in utero market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of spina bifida in utero across the seven major markets?
What is the number of prevalent cases (2018-2034) of spina bifida in utero by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of spina bifida in utero by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with spina bifida in utero across the seven major markets?
What is the size of the spina bifida in utero patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of spina bifida in utero?
What will be the growth rate of patients across the seven major markets?
Spina Bifida In Utero: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for spina bifida in utero drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the spina bifida in utero market?
What are the key regulatory events related to the spina bifida in utero market?
What is the structure of clinical trial landscape by status related to the spina bifida in utero market?
What is the structure of clinical trial landscape by phase related to the spina bifida in utero market?
What is the structure of clinical trial landscape by route of administration related to the spina bifida in utero market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SPINA BIFIDA IN UTERO - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 SPINA BIFIDA IN UTERO - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 SPINA BIFIDA IN UTERO - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 SPINA BIFIDA IN UTERO - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 SPINA BIFIDA IN UTERO - UNMET NEEDS
10 SPINA BIFIDA IN UTERO - KEY ENDPOINTS OF TREATMENT
11 SPINA BIFIDA IN UTERO - MARKETED PRODUCTS
11.1 List of Spina Bifida In Utero Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 SPINA BIFIDA IN UTERO - PIPELINE DRUGS
12.1 List of Spina Bifida In Utero Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. SPINA BIFIDA IN UTERO - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. SPINA BIFIDA IN UTERO – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 SPINA BIFIDA IN UTERO - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Spina Bifida In Utero - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Spina Bifida In Utero - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Spina Bifida In Utero - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Spina Bifida In Utero - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Spina Bifida In Utero - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Spina Bifida In Utero - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Spina Bifida In Utero - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Spina Bifida In Utero - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Spina Bifida In Utero - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Spina Bifida In Utero - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Spina Bifida In Utero - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Spina Bifida In Utero - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Spina Bifida In Utero - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Spina Bifida In Utero - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Spina Bifida In Utero - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Spina Bifida In Utero - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Spina Bifida In Utero - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Spina Bifida In Utero - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Spina Bifida In Utero - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Spina Bifida In Utero - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Spina Bifida In Utero - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Spina Bifida In Utero - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Spina Bifida In Utero - Access and Reimbursement Overview
16 SPINA BIFIDA IN UTERO - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 SPINA BIFIDA IN UTERO MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 SPINA BIFIDA IN UTERO MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SPINA BIFIDA IN UTERO - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 SPINA BIFIDA IN UTERO - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 SPINA BIFIDA IN UTERO - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 SPINA BIFIDA IN UTERO - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 SPINA BIFIDA IN UTERO - UNMET NEEDS
10 SPINA BIFIDA IN UTERO - KEY ENDPOINTS OF TREATMENT
11 SPINA BIFIDA IN UTERO - MARKETED PRODUCTS
11.1 List of Spina Bifida In Utero Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 SPINA BIFIDA IN UTERO - PIPELINE DRUGS
12.1 List of Spina Bifida In Utero Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. SPINA BIFIDA IN UTERO - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. SPINA BIFIDA IN UTERO – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 SPINA BIFIDA IN UTERO - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Spina Bifida In Utero - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Spina Bifida In Utero - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Spina Bifida In Utero - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Spina Bifida In Utero - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Spina Bifida In Utero - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Spina Bifida In Utero - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Spina Bifida In Utero - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Spina Bifida In Utero - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Spina Bifida In Utero - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Spina Bifida In Utero - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Spina Bifida In Utero - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Spina Bifida In Utero - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Spina Bifida In Utero - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Spina Bifida In Utero - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Spina Bifida In Utero - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Spina Bifida In Utero - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Spina Bifida In Utero - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Spina Bifida In Utero - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Spina Bifida In Utero - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Spina Bifida In Utero - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Spina Bifida In Utero - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Spina Bifida In Utero - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Spina Bifida In Utero - Access and Reimbursement Overview
16 SPINA BIFIDA IN UTERO - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 SPINA BIFIDA IN UTERO MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 SPINA BIFIDA IN UTERO MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
